Twenty adult epileptic out-patients who had received anticonvulsant therapy for a mean duration of 15 years were assessed for clinical, biochemical, radioisotopic and bone biopsy evidence of osteomalacia. Occasional biochemical abnormalities were demonstrated but no individual subject was found to have osteomalacia. There is increasing evidence to cast doubt on the existence of a strong relationship between anticonvulsant drugs and osteomalacia. This evidence is reviewed and it is concluded that in the presence of adequate sunlight exposure anticonvulsant therapy alone is most unlikely to lead to osteomalacia in adults.
Get full access to this article
View all access options for this article.
References
1.
KruseR. Osteopathein bei antiepileptischer Langyeittherapie. Monatsschr Kinderheilkd1968; 116:378–381.
2.
DentCERichensARoweDFJStampTCB. Osteomalacia with longterm anticonvulsant therapy in epilepsy. Br Med J1970; 4:69–72.
3.
LifshitzFMacLarenNK. Vitamin-D dependent rickets in institutionalised mentally retarded children receiving longterm anticonvulsant therapy. J Pediatr1973; 83:612–620.
4.
HahnTJAvioliLV. Anticonvulsant osteomalacia. Arch Int Med1975; 135:997–1000.
5.
PalmerKTSmithAETaylorBB. Anticonvulsant induced osteomalacia. Age Ageing1977; 6:228–231.
6.
HunterJMaxwellJDStewartDAParsonsVWilliamsR. Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J1971; 4:202–204.
7.
StampTCBRoundJMRoweDJFHaddadJG. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J1972; 4:9–12.
8.
TolmanKGJubizWSanellaJJMadsenJABelseyREGoldsmithRSFrestonJW. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics1975; 56:45–51.
9.
HahnTJHendinBAScharpCRBoisseauVCHaddadJGJr. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med1975; 292:550–554.
10.
BouillonRReynaertJClaesJHLissensWDe MoorP. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium and parathyroid hormone. J Clin Endocrinol Metab1975; 41:1130–1135.
11.
RichensARoweDJF. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J1970; 4:73–76.
12.
SotaniemiEAHakkarainenHKPuranenJALahtiRO. Radiologic bone changes and hypocalcaemia with anticonvulsant therapy in epilepsy. Ann Intern Med1972; 77:389–394.
13.
HahnTJHendinBAScharpCRHaddadJGJr. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol level in adults. N Engl J Med1972; 287:900–904.
14.
ChristiansenCRodbroPLundM. Incidence of anticonvulsant osteomalacia and effect of vitamin D: Controlled therapeutic trial. Br Med J1973; 4:695–701.
15.
MosekildeLMelsenF. Anticonvulsant osteomalacia determined by quantitative analysis of bone changes. Acta Med Scand1976; 199:349–355.
16.
HahnTJHalsteadLR. Anticonvulsant drug induced osteomalacia: Alterations in mineral metabolism and response to vitamin D3 administration. Calcif Tiss Int1979; 27:13–18.
17.
MaryaRKKhattarVPBansalRK. Occult anticonvulsant osteomalacia in North India. Nutr Metab1979; 23:167–171.
18.
WeismanYFattalAEisenbergZHarelSSpirerZHarellA. Decreased serum 24, 25-dihydroxy vitamin D concentrations in children receiving chronic anticonvulsant therapy. Br Med J1979; 2:521–523.
19.
MelsenFMosekildeLChristensenMSLundBSorensenOH. Inter-relationship between serum 25-hydroxycholecalciferol, serum parathyroid hormone and morphometric bone changes in anticonvulsant osteomalacia. Therapeutic effect of vitamin D2. Calcif Tiss Res Suppl1977; 22:473–478.
20.
JubizWHausslerMRMcCainTATolmanKG. Plasma 1, 25-dihydroxy vitamin D levels in patients receiving anticonvulsant drugs. J Clin Endocrinol Metab1977; 44:617–621.
21.
LevinsonJCKentGNWorthGKRetallackRW. Anticonvulsant induced increase in 25-hydroxy-vitamin D3-1αhydroxylase. Endocrinology1977; 101:1898–1901.
22.
StanburySWMawerEB. Clinical aspects of vitamin D metabolism in man. In VitaminDLawsonDEM. Ed. London: Academic Press1978:368.
23.
FogelmanIBessentRGTurnerJGCitrinDLBoyleITGreigWR. The use of whole body retention of 99m-Tc diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med1978; 19:270–275.
24.
FogelmanIBessentRGBeastallGHBoyleIT. Estimation of skeletal involvement in primary hyperparathyroidism. Ann Intern Med1980; 92:65–67.
25.
KennedyACAllamBFBoyleITNukiGRooneyPJBuchananWW. Abnormalities in mineral metabolism suggestive of parathyroid overactivity in rheumatoid arthritis. Curr Med Res Opin1975; 3:345–358.
26.
SkillenAWPieridesAM. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta1976; 72:245–251.
27.
JuntzmanR. Drugs and enzyme induction. Ann Rev Pharmacol1969; 9:21–36.
28.
WarkJDLarkinsRGPerry-KeeneDPeterCTRossDLSlomanJG. Chronic diphenylhydantoin therapy does not reduce plasma 25-hydroxyvitamin D. Clin Endocrinol1979; 11:267–274.
29.
KazamarsuriH. Elevated serum alkaline phosphatase levels in epilepsy during diphenylhydantoin therapy. N Engl J Med1970; 283:1411–1412.
30.
DymlingJFLidgrenLWalloeA. Biochemical variables related to calcium metabolism in epileptics. Acta Med Scand1979; 205:401–404.
31.
SilverJNealeGThompsonGR. Effect of phenobarbitone treatment on vitamin D metabolism in mammals. Clin Sci1974; 46:433–448.
32.
HarrisMRoweDJFDarbyAJ. Anticonvulsant osteomalacia induced in the rat by diphenylhydantoin. Calcif Tiss Res1978; 25:13–17.
33.
FogelmanIBessentRGCohenHNHartDMLindsayR. Skeletal uptake of diphosphonate: Method for prediction of post-menopausal osteoporosis. Lancet1980; 2:667–670.
34.
FogelmanI. The value of 24 hour skeletal uptake of diphosphonate in the exclusion of metabolic bone disease. Nucl Med Comm1980; 1:351–356.
35.
HahnTJ. Bone complications of anticonvulsants. Drugs1976; 12:201–211.
36.
DunniganMGGardnerMD. Serum alkaline phosphatase in urban and semi-rural Scottish children. Scot Med J1965; 10:325–328.
37.
CookeWISwanCHJAsquithPMelikianVMcFeeyWE. Serum alkaline phosphatase and rickets in urban school children. Br Med J1973; 1:324–327.
38.
PreeceMATomlinsonSRibotCAPietrekJKornHTDaviesDMFordJADunniganMGO'RiordanJLH. Studies of vitamin D deficiency in man. Q J Med1975; 44:575–580.
39.
PittetPGDavieMLawsonDEM. Role of nutrition in the development of osteomalacia in the elderly. Nutr Metab1979; 23:109–116.
40.
ApantakuJBAfonjaOABoydAE. The effect of longterm anticonvulsant therapy on serum calcium, phosphate and alkaline phosphatase in Nigerian epileptic patients. Trop Geogr Med1975; 27:418–421.
41.
PapapoulosSEClemensTLFraherLJGleedJO'RiordanJLH. Effect of vitamin D3 or 1, 25-dihydroxycholecalciferol on metabolites of vitamin D in human vitamin D deficiency. Lancet1980; 2:612–615.
42.
ChristensenCKLundBLundBJSorensenOHNeilsenHEMosekildeL. Reduced 1, 25-dihydroxyvitamin D and 24, 25-dihydroxyvitamin D in epileptic patients receiving chronic combined anticonvulsant therapy. Metab Bone Dis and Rel Res1981; 3:17–22.
43.
DavieMLawsonDEM. Response of plasma 25-0H D to standardised ultra violet radiation. In: Vitamin D Basic Research and its Clinical Applications. NormanAWSchaeferKHerrathDVGrigoleitHGCoburnJWDe LucaHFMawerEBSudaT, Eds. New York: Walter de Gruyter1979;163–164.
44.
BardenHSMazessRBRosePGMcAweeneyW. Bone mineral status measured by direct photon absorptiometry in institutionalised adults receiving longterm anticonvulsant therapy and multivitamin supplementation. Calcif Tiss Int1980; 31:117–121.
45.
DavieMJungRTEmbersonCChalmersTMHunterJD. Vitamin D metabolism in subjects receiving anticonvulsant drugs. Clin Sci1979; 57:6–7.
46.
LivingstoneSBermanWPauliLL. Anticonvulsant drugs and vitamin D metabolism. JAMA1973; 224:1634–1635.
47.
FrameBParfittAM. Osteomalacia: Current concepts. Ann Intern Med1978; 89:966–982.
